Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CStone Pharmaceuticals (2616.HK)
Shanghai, CN
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.78% | +3.21% | -13.44% | +20.51% | +31.75% | +52.75% | +103.28% | +181.47% | -39.84% | -37.40% | -37.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -1 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-33.8% Q4'25: +8.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-333.6% Q4'25: +11.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-187.6% Q4'25: -25.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-154.3% Q4'25: -63.0% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-892.2% Q4'25: -1,190.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+8.8% Q4'25: +14.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.86× Q4'25: -0.66× (vs Q4'23)
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
243.72M
est: 260.66M (-6.5%)
|
481.36M
est: 471.96M (+2.0%)
|
463.84M
est: 424.67M (+9.2%)
|
407.21M
est: 385.86M (+5.5%)
|
269.58M
est: 216.70M (+24.4%)
|
477.11M
399.19M – 606.20M
+120.2% YoY
|
1.52B
467.56M – 4.17B
+219.1% YoY
|
1.05B
1.00B – 1.10B
-31.1% YoY
|
| EBITDA |
-1.90B
est: -199.59M (-849.6%)
|
-849.66M
est: -361.38M (-135.1%)
|
-297.23M
est: -325.17M (+8.6%)
|
-76.43M
est: -295.45M (+74.1%)
|
-403.85M
est: -165.92M (-143.4%)
|
-365.32M
-464.17M – -305.66M
-120.2% YoY
|
-1.17B
-3.20B – -358.01M
-219.1% YoY
|
-803.64M
-840.07M – -767.21M
+31.1% YoY
|
| EBIT |
-1.92B
est: -208.55M (-819.6%)
|
-894.20M
est: -377.61M (-136.8%)
|
-355.42M
est: -339.77M (-4.6%)
|
-95.36M
est: -308.72M (+69.1%)
|
-415.83M
est: -173.38M (-139.8%)
|
-381.73M
-485.01M – -319.39M
-120.2% YoY
|
-1.22B
-3.34B – -374.09M
-219.1% YoY
|
-839.73M
-877.79M – -801.66M
+31.1% YoY
|
| Net Income |
-1.92B
est: -1.79B (-7.3%)
|
-902.68M
est: -750.34M (-20.3%)
|
-367.23M
est: -132.38M (-177.4%)
|
-91.21M
est: -42.96M (-112.3%)
|
-437.00M
est: -291.44M (-49.9%)
|
-3.33M
-6.22M – -437.1K
+98.9% YoY
|
594.79M
-159.75M – 1.60B
+17,970.5% YoY
|
80.89M
-279.47M – 535.65M
-86.4% YoY
|
| SGA |
472.99M
est: 204.20M (+131.6%)
|
390.48M
est: 369.74M (+5.6%)
|
248.07M
est: 368.28M (-32.6%)
|
166.94M
est: 334.62M (-50.1%)
|
172.36M
est: 187.92M (-8.3%)
|
413.76M
346.19M – 525.71M
+120.2% YoY
|
1.32B
405.48M – 3.62B
+219.1% YoY
|
910.19M
868.93M – 951.45M
-31.1% YoY
|
| EPS |
-1.65
est: -1.40 (-17.7%)
|
-0.77
est: -0.82 (+5.9%)
|
-0.29
est: -0.10 (-179.3%)
|
-0.07
est: -0.02 (-257.6%)
|
-0.31
est: -0.21 (-47.7%)
|
0.00
0.00 – 0.00
+98.9% YoY
|
0.52
-0.12 – 1.15
+21,699.9% YoY
|
0.09
-0.20 – 0.39
-82.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.43% | 279.8K | 0.59% |
| 2 | UBS Solactive China Technology UCITS ETF USD acc CQQQ.SW | 0.10% | 362.7K | 0.47% |
| 3 | UBS Solactive China Technology UCITS ETF hEUR acc CITE.MI | 0.09% | 336.7K | 0.50% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.06% | 42.8K | 0.74% |
| 5 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.05% | 386.1K | 0.65% |
| 6 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 160.6K | 0.72% |
| 7 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.04% | 137.0K | 0.74% |
| 8 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.04% | 214.7K | 0.55% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.03% | 4.09M | 0.06% |
| 10 | State Street SPDR S&P China ETF GXC | 0.02% | 91.3K | 0.59% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jianxin Yang | Chief Executive Officer, President of R&D and Executive Director | 8M | — |
| Michael J. Choi | Chief Business & Strategy Officer | — | male |
| Qingmei Shi | Senior Vice President & Chief Medical Officer | — | — |
| Qinzhou Qi | VP and Head of R&D Management & Chief of Staff to the CEO | — | — |
| Weicong Ni | CFO & Company Secretary | — | female |
| Ying Hua Zhang | Senior Vice President & Chief Operating Officer | — | female |
| Yujuan La | Senior Vice President of Product Development | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2616.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
